Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Avantis International Equity ETF (NY:AVDE)

79.69 +0.62 (+0.78%)
Streaming Delayed Price Updated: 2:00 PM EDT, Oct 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Avantis International Equity ETF

< Previous 1 2 Next >
Novo Nordisk Reportedly Slashes Workforce At Its US Wegovy Manufacturing Plant
Via Stocktwits
Novo Nordisk To Reportedly Cut Yearly Bonus For Denmark Employees: Retail Expects Stock To Hit $80 By Year-End
Via Stocktwits
Budweiser Maker’s Stock Gets Crushed After Q2 Gloom — Retail Traders Feel 'Drop Is A Bit Unjustified'
U.S.-listed shares of the world's largest brewer marked their worst day in over five years after the company missed revenue and volume estimates. 
Via Stocktwits
Topics Government
US Judge Upholds FDA Decision To Remove Wegovy, Ozempic From Shortage List In Move Against Compounding Pharmacies
The judge said that the FDA had appropriately weighed supply and demand data for the drugs and properly removed them from the shortage list, Reuters reported. 
Via Stocktwits
Topics Lawsuit
Novo Nordisk’s Plan To Start Late-Stage Trial Of Investigational Obesity Drug Amycretin In 2026 Gets Retail Talking
The decision to advance the study of subcutaneous and oral Amycretin into the late stage is based on feedback received from regulators following mid-stage studies. 
Via Stocktwits
Novo Nordisk’s $812M Deal With Deep Apple Lifts Retail Mood, Chatter Spikes To High Levels
Separately, chip-maker Nvidia also announced a collaboration with Novo Nordisk to accelerate drug discovery efforts through innovative AI use cases. 
Via Stocktwits
Topics Artificial Intelligence Economy
Toyota Industries Likely To Accept $42B Takeover Bid From Toyota Motor And Group Companies, Says Report: Retail’s Undecided
The consortium is expected to take Toyota Industries private after it accepts the tender offer, with the takeover bid estimated at 6 trillion yen, or approximately $42 billion. 
Via Stocktwits
Topics Supply Chain
Toyota Records Fourth Straight Month Of Sales Jump In April: But Retail’s Not Yet Convinced
The company reported a 25% jump in sales of electrified vehicles last month, owing to a 24% increase in sales of hybrid electric vehicles in particular, which touched 378,976 units. 
Via Stocktwits
Topics Government World Trade
Novo Nordisk To Sell Wegovy For $199 A Month As Compounding Ban Nears: Retail’s Bullish
The offer will be valid through June 30 and aims to encourage patients who previously used compounded versions of the drug to move to Wegovy. 
Via Stocktwits
Novo Nordisk CEO Lars Jørgensen Steps Down Amid Challenges, Retail Chatter Spikes
The company said it would announce the next CEO in “due course,” but did not provide a more definite timeline. 
Via Stocktwits
Budweiser Maker AB InBev Plans $300M Investment To Expand US Production: Retail Turns Bullish
As part of the plan, the company will also open a new plant in Ohio. 
Via Stocktwits
Topics Government
Toyota Expects 21% Profit Decline In FY26: Retail’s In Wait-And-Watch Mode
The company said that the new forecast includes a negative impact of 180 billion yen from U.S. tariffs for April and May, and an estimated 745 billion yen impact from the effects of the foreign... 
Via Stocktwits
Topics World Trade
Novo Nordisk Stock Rises Pre-Market On Q1 Beat Despite Lowering Outlook – Retail’s Elated
Sales of Novo Nordisk’s flagship weight loss drug Wegovy surged 85% in the first quarter of the fiscal year 2025, while its diabetes treatment Ozempic posted an 18% increase. 
Via Stocktwits
Topics Earnings Law Enforcement
Why Is UBS Stock Trading Lower On Wednesday?
UBS Group AG shares are down 1% Y/Y, with revenues of $12.56 billion missing consensus. CEO remains focused on clients and financial targets. 
Via Benzinga
Novo Nordisk’s Weight-Loss Drug Wegovy Launched In Thailand, Marks Entry Into Southeast Asia
Enrico Canal Bruland, vice president and general manager of Novo's Thai subsidiary, told Reuters that the firm received approval from the Thai FDA in 2023. 
Via Stocktwits
Novo Nordisk Wins Another Legal Battle Against Compounding Of Wegovy, Ozempic: Retail’s Bullish
Steve Benz, legal and US general counsel of Novo Nordisk, said the company is “pleased” that the court rejected the compounders' attempts to “undermine” the FDA's decision that the shortages of Wegovy... 
Via Stocktwits
Topics Lawsuit
Genmab Stock Rises On Strong Darzalex Sales In Q1: Retail Remains Extremely Bullish
Genmab receives royalties on the worldwide net sales of Darzalex, both the intravenous and subcutaneous products, under J&J's exclusive worldwide license to develop, manufacture, and commercialize... 
Via Stocktwits
Topics Stocks
Novo Nordisk Warns Against Counterfeit Ozempic In US: Retail’s Unmoved
The company said the seized counterfeit products feature lot number PAR0362 and illegitimate serial numbers beginning with the first eight digits, 51746517. 
Via Stocktwits
Topics Economy
Novo Nordisk’s Controlling Shareholder Novo Holdings Reports Record Total Income, Investment Returns In 2024: Retail Stays Bullish
The company said that its earnings consist of income from dividends and the share repurchase programmes of Novo Group companies Novo Nordisk A/S and Novonesis A/S, as well as returns from its... 
Via Stocktwits
Novo Nordisk Stock Slips After BofA, Morgan Stanley Slash Price Targets – But Retail Goes Contrarian
Bank of America analysts said Novo Nordisk might miss first-quarter estimates. According to TheFly, they expect the company to lower its full-year sales guidance from 16%-24% at constant exchange rates... 
Via Stocktwits
Novo Nordisk Signs $2B Deal For Obesity Drug With Chinese Biotech: Retail Sentiment Improves
Novo Nordisk will obtain exclusive worldwide rights to develop, manufacture, and commercialize the drug UBT251, while United Biotechnology will, however, retain the rights to the drug in mainland... 
Via Stocktwits
Sony Stock Surges After Q3 Earnings Beat, Raised Outlook: Retail’s Not Convinced
For full-year 2024, Sony expects revenue to be about JPY 13.2 trillion ($876 billion), 4% higher than its previous outlook. 
Via Stocktwits
Topics Earnings
Sony Beats Q3 Earnings Expectations, PS5 And Streaming Revenues Growth Prompts Outlook Raise
PlayStation parent Sony Group Corp reported strong Q3 results, with sales of $28.97B, beating estimates. EPS of $0.41 also beat expectations. PS5 sales drove growth. 
Via Benzinga
Toyota Downgraded After Second Straight Profit Drop, But Stock Climbs As Annual Outlook Improves: Retail Stays Optimistic
Toyota also announced plans to establish a wholly owned company in Shanghai to develop and produce Lexus BEVs and batteries. 
Via Stocktwits
UBS Reports Strong Q4 Profit Growth, Warns Of Interest Income Decline
UBS Group AG shares down after reporting $11.6B sales, 7% Y/Y growth & EPS of $0.23, beating consensus. Global Wealth Management's net new assets rose 10% Y/Y. 
Via Benzinga
STMicroelectronics Q4 Earnings: 22% Revenue Drop, Sees Challenges With Lower Industrial and Auto Demand, Issues Weak Q1 Outlook
STMicroelectronics reported Q4 net revenues of $3.32B, beating analyst estimates. EPS of $0.37 missed expectations. Net revenues aligned with outlook, driven by Personal Electronics. Book-to-bill ratio... 
Via Benzinga
Sony Cancels Two Live-Service Games, Stays Committed to Long-Term Monetization
PlayStation cancels unannounced live-service projects at Bend Studio and Bluepoint Games. Sony remains invested in live-service games and sold 3.8M PS5 units in Q2. Gaming industry faces challenges,... 
Via Benzinga
What's Going With UBS Shares On Wednesday?
UBS reaffirms commitment to Swiss market, to maintain $414B in loans despite rumors of cuts. 
Via Benzinga
UBS Liquidates $2B Credit Suisse Real Estate Fund Amid Market Slump: Report
UBS Group AG reportedly discloses $2B real estate fund from Credit Suisse into 'orderly liquidation' due to significant decline in value. 
Via Benzinga
UBS Q2 Earnings Beats: Wealth Management Shines, Cost Savings Accelerate & More
UBS Group reported strong Q2 sales of $11.9B, beating consensus. Gross cost savings of $0.9B achieved, with $7B expected by 2024. Merger with Credit Suisse complete, focusing on growth and cost... 
Via Benzinga
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.